Laurus Labs Limited gets Board approval for the investment of an amount of Rs. equivalent of up to €5 five million in KRKA Pharma Private Limited, a joint venture of the company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs. equivalent of about €5 million in KRKA. The existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs Limited shall remain the same post-investment.

The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market.

This investment aligns with the company’s strategic growth plans and long-term business objectives. The investment by the company is expected to be completed on or before 31st December, 2025.